Deep Track Capital, LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Deep Track Capital, LP reported 69 stock positions worth $3.1 billion. Its top holding was Argenx SE - ADR (ARGX) at 6.3% of the portfolio, followed by Dynavax Technologies (DVAX, 4.5%) and Guardant Health (GH, 4.4%). Compared with Q2 2024, it opened 10 new positions, sold out of 8, added to 21 and reduced 22. The biggest buy was a new position in MBX Biosciences (MBX) and the biggest sale an exit from Amgen (AMGN).
- Most Recent 13F
- Q2 2026
- Location
- GREENWICH, CT
- CIK
- 0001856083
- Portfolio Value
- $3.1B (Q3 2024)
- SEC Filing
- 0001856083-24-000007 ↗ filed Nov 14, 2024
Holdings Value
Holdings 69 stocks · $3.1B
| ARGX Argenx SE - ADR | 6.32% | 365,000 | $197.9M | Reduce -8.8% |
| DVAX Dynavax Technologies Corp. | 4.46% | 12,526,486 | $139.5M | Add +14.9% |
| GH Guardant Health Inc. | 4.39% | 6,000,560 | $137.7M | Add +33.4% |
| APLS Apellis Pharmaceuticals Inc. | 4.05% | 4,400,654 | $126.9M | Add +76.0% |
| IMVT Immunovant Inc. | 3.96% | 4,347,464 | $123.9M | Add +50.8% |
| SWTX Springworks Therapeutics Inc. | 3.93% | 3,843,900 | $123.2M | Add +3.9% |
| DYN Dyne Therapeutics Inc. | 3.76% | 3,282,000 | $117.9M | Reduce -17.9% |
| ITCI Intra-Cellular Therapies Inc. | 3.74% | 1,600,693 | $117.1M | Add +4.1% |
| OCUL Ocular Therapeutix Inc. | 3.53% | 12,721,460 | $110.7M | No change |
| NTLA Intellia Therapeutics Inc. | 3.25% | 4,950,000 | $101.7M | Add +3.1% |
| ALKS Alkermes PLC | 3.13% | 3,500,000 | $98.0M | No change |
| VRNA Verona Pharma Ltd. | 2.92% | 3,180,025 | $91.5M | Reduce -20.5% |
| IONS Ionis Pharmaceuticals Inc. | 2.81% | 2,200,000 | $88.1M | Add +10.0% |
| NRIX Nurix Therapeutics Inc. | 2.77% | 3,868,104 | $86.9M | Reduce -3.1% |
| VRDN Viridian Therapeutics Inc. | 2.72% | 3,750,945 | $85.3M | Reduce -4.4% |
| BCYC Bicycle Therapeutics PLC-ADR | 2.56% | 3,548,001 | $80.3M | Add +1.6% |
| MBX MBX Biosciences Inc. | 2.50% | 3,018,935 | $78.4M | New |
| AXSM Axsome Therapeutics Inc. | 2.46% | 857,219 | $77.0M | Reduce -53.7% |
| PLRX Pliant Therapeutics Inc. | 2.14% | 5,972,257 | $66.9M | No change |
| APGE Apogee Therapeutics Inc. | 1.88% | 1,000,000 | $58.7M | No change |
| AUTL Autolus Therapeutics PLC | 1.77% | 15,272,172 | $55.4M | No change |
| GPCR Structure Therapeutics Inc. | 1.71% | 1,220,508 | $53.6M | Add +28.5% |
| OLMA Olema Pharmaceuticals Inc. | 1.52% | 4,000,000 | $47.8M | No change |
| TERN Terns Pharmaceuticals Inc. | 1.48% | 5,576,558 | $46.5M | Reduce -8.6% |
| FDMT 4D Molecular Therapeutics Inc. | 1.41% | 4,096,452 | $44.3M | Add +0.9% |
| ABVX Abivax SA-ADR | 1.32% | 3,579,209 | $41.2M | Reduce -14.4% |
| TGTX TG Therapeutics Inc. | 1.29% | 1,725,000 | $40.3M | Reduce -39.9% |
| MIND MEDICINE MINDMED INC | 1.28% | 7,065,099 | $40.2M | Add +15.8% |
| KURA Kura Oncology Inc. | 1.22% | 1,963,505 | $38.4M | Add +410.3% |
| GERN Geron Corp. | 1.10% | 7,575,049 | $34.4M | Reduce -41.7% |
| CYTK Cytokinetics Inc. | 1.06% | 629,906 | $33.3M | Add +375.4% |
| ORKA Oruka Therapeutics Inc. | 0.97% | 1,235,187 | $30.3M | New |
| ANIP Ani Pharmaceuticals Inc. | 0.96% | 504,828 | $30.1M | Add +8.3% |
| SYRE Spyre Therapeutics Inc. | 0.94% | 1,000,000 | $29.4M | Reduce -43.1% |
| EWTX Edgewise Therapeutics Inc. | 0.94% | 1,100,536 | $29.4M | Add +490.5% |
| KYMR Kymera Therapeutics Inc. | 0.91% | 600,326 | $28.4M | Reduce -60.0% |
| KRRO Korro Bio Inc. | 0.91% | 850,000 | $28.4M | Add +10.3% |
| RNAM Avidity Biosciences Inc. | 0.70% | 475,000 | $21.8M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 0.69% | 1,350,000 | $21.6M | New |
| ALEC Alector Inc. | 0.69% | 4,631,998 | $21.6M | No change |
| NKTR Nektar Therapeutics | 0.66% | 15,922,655 | $20.7M | Reduce -10.9% |
| ETNB 89BIO Inc. | 0.65% | 2,766,512 | $20.5M | Add +20.6% |
| BCAX Bicara Therapeutics Inc. | 0.65% | 796,852 | $20.3M | New |
| AKRO Akero Therapeutics Inc. | 0.63% | 689,784 | $19.8M | New |
| FATE Fate Therapeutics Inc. | 0.62% | 5,572,607 | $19.5M | No change |
| SLN Silence Therapeutics PLC-ADR | 0.58% | 1,000,000 | $18.2M | Reduce -26.5% |
| ENGN Engene Holdings Inc. | 0.55% | 2,607,633 | $17.2M | Add +15.9% |
| EDIT Editas Medicine Inc. | 0.53% | 4,900,334 | $16.7M | Reduce -18.3% |
| XNCR Xencor Inc. | 0.51% | 800,000 | $16.1M | New |
| PYXS Pyxis Oncology Inc. | 0.49% | 4,184,100 | $15.4M | No change |
| CNTX Context Therapeutics Inc. | 0.46% | 7,419,355 | $14.5M | No change |
| HELP Cybin Inc. | 0.43% | 1,529,987 | $13.6M | Add +0.7% |
| ZURA Zura Bio Ltd. | 0.43% | 3,283,783 | $13.3M | No change |
| IVVD Invivyd Inc. | 0.36% | 10,953,937 | $11.2M | No change |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 0.35% | 2,169,143 | $11.0M | Reduce -44.5% |
| INO Inovio Pharmaceuticals Inc. | 0.33% | 1,804,366 | $10.4M | Reduce -12.7% |
| AVTX Avalo Therapeutics Inc. | 0.29% | 967,000 | $9.2M | New |
| NMRA Neumora Therapeutics Inc. | 0.24% | 567,428 | $7.5M | New |
| TVTX Travere Therapeutics Inc. | 0.24% | 531,857 | $7.4M | Reduce -92.8% |
| VIGL Vigil Neuroscience Inc. | 0.17% | 1,553,996 | $5.3M | Add +160.2% |
| RGLS Regulus Therapeutics Inc. | 0.16% | 3,262,564 | $5.1M | No change |
| ALLK Allakos LLC | 0.10% | 5,000,000 | $3.3M | No change |
| ANRO Alto Neuroscience Inc. | 0.08% | 219,648 | $2.5M | Reduce -57.1% |
| PRTA Prothena Corp. PLC | 0.07% | 140,000 | $2.3M | New |
| RLMD Relmada Therapeutics Inc. | 0.07% | 674,833 | $2.2M | Reduce -45.4% |
| ALGS Aligos Therapeutics Inc. | 0.07% | 244,110 | $2.1M | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.06% | 828,485 | $1.8M | No change |
| MGX Metagenomi Therapeutics Inc. | 0.02% | 307,500 | $667K | Reduce -34.0% |
| SRRK Scholar Rock Holding Corp. | 0.01% | 48,100 | $385K | Reduce -87.1% |
Options reported separately and not counted above: AXSM calls ($18.0M), NMRA calls ($2.4M).
Portfolio Sells Q2 2024 → Q3 2024
| AMGN Amgen Inc. | Sold out | 0.00% | −5.37 |
| INSM Insmed Inc. | Sold out | 0.00% | −4.00 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −3.63 |
| AXSM Axsome Therapeutics Inc. | Reduce -53.7% | 2.46% | −1.99 |
| TVTX Travere Therapeutics Inc. | Reduce -92.8% | 0.24% | −1.57 |
| HLVX Hillevax Inc. | Sold out | 0.00% | −0.79 |
| GERN Geron Corp. | Reduce -41.7% | 1.10% | −0.55 |
| PRAX Praxis Precision Medicines I | Sold out | 0.00% | −0.48 |
| CLYM Climb Bio Inc. | Reduce -44.5% | 0.35% | −0.48 |
| DYN Dyne Therapeutics Inc. | Reduce -17.9% | 3.76% | −0.45 |
| KYMR Kymera Therapeutics Inc. | Reduce -60.0% | 0.91% | −0.43 |
| ABVX Abivax SA-ADR | Reduce -14.4% | 1.32% | −0.33 |
| EDIT Editas Medicine Inc. | Reduce -18.3% | 0.53% | −0.30 |
| SYRE Spyre Therapeutics Inc. | Reduce -43.1% | 0.94% | −0.29 |
| TGTX TG Therapeutics Inc. | Reduce -39.9% | 1.29% | −0.24 |
| SLN Silence Therapeutics PLC-ADR | Reduce -26.5% | 0.58% | −0.19 |
| INO Inovio Pharmaceuticals Inc. | Reduce -12.7% | 0.33% | −0.17 |
| AGEN Agenus Inc. | Sold out | 0.00% | −0.16 |
| RPTX Repare Therapeutics Inc. | Sold out | 0.00% | −0.09 |
| ANRO Alto Neuroscience Inc. | Reduce -57.1% | 0.08% | −0.08 |
| SRRK Scholar Rock Holding Corp. | Reduce -87.1% | 0.01% | −0.08 |
| COGT Cogent Biosciences Inc. | Sold out | 0.00% | −0.08 |
| RLMD Relmada Therapeutics Inc. | Reduce -45.4% | 0.07% | −0.04 |
| MGX Metagenomi Therapeutics Inc. | Reduce -34.0% | 0.02% | −0.04 |
| NKTR Nektar Therapeutics | Reduce -10.9% | 0.66% | −0.00 |
| TERN Terns Pharmaceuticals Inc. | Reduce -8.6% | 1.48% | +0.24 |
| NRIX Nurix Therapeutics Inc. | Reduce -3.1% | 2.77% | +0.29 |
| ARGX Argenx SE - ADR | Reduce -8.8% | 6.32% | +1.18 |
| VRNA Verona Pharma Ltd. | Reduce -20.5% | 2.92% | +1.19 |
| VRDN Viridian Therapeutics Inc. | Reduce -4.4% | 2.72% | +1.20 |
Portfolio Buys Q2 2024 → Q3 2024
| MBX MBX Biosciences Inc. | New | 2.50% | +2.50 |
| IMVT Immunovant Inc. | Add +50.8% | 3.96% | +1.68 |
| APLS Apellis Pharmaceuticals Inc. | Add +76.0% | 4.05% | +1.19 |
| KURA Kura Oncology Inc. | Add +410.3% | 1.22% | +0.99 |
| ORKA Oruka Therapeutics Inc. | New | 0.97% | +0.97 |
| CYTK Cytokinetics Inc. | Add +375.4% | 1.06% | +0.85 |
| EWTX Edgewise Therapeutics Inc. | Add +490.5% | 0.94% | +0.84 |
| DVAX Dynavax Technologies Corp. | Add +14.9% | 4.46% | +0.80 |
| RNAM Avidity Biosciences Inc. | New | 0.70% | +0.70 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 0.69% | +0.69 |
| BCAX Bicara Therapeutics Inc. | New | 0.65% | +0.65 |
| AKRO Akero Therapeutics Inc. | New | 0.63% | +0.63 |
| GPCR Structure Therapeutics Inc. | Add +28.5% | 1.71% | +0.60 |
| ITCI Intra-Cellular Therapies Inc. | Add +4.1% | 3.74% | +0.59 |
| GH Guardant Health Inc. | Add +33.4% | 4.39% | +0.51 |
| XNCR Xencor Inc. | New | 0.51% | +0.51 |
| BCYC Bicycle Therapeutics PLC-ADR | Add +1.6% | 2.56% | +0.45 |
| AVTX Avalo Therapeutics Inc. | New | 0.29% | +0.29 |
| NMRA Neumora Therapeutics Inc. | New | 0.24% | +0.24 |
| KRRO Korro Bio Inc. | Add +10.3% | 0.91% | +0.13 |
| ETNB 89BIO Inc. | Add +20.6% | 0.65% | +0.10 |
| VIGL Vigil Neuroscience Inc. | Add +160.2% | 0.17% | +0.10 |
| ANIP Ani Pharmaceuticals Inc. | Add +8.3% | 0.96% | +0.08 |
| PRTA Prothena Corp. PLC | New | 0.07% | +0.07 |
| NTLA Intellia Therapeutics Inc. | Add +3.1% | 3.25% | +0.04 |
| MIND MEDICINE MINDMED INC | Add +15.8% | 1.28% | −0.03 |
| IONS Ionis Pharmaceuticals Inc. | Add +10.0% | 2.81% | −0.03 |
| HELP Cybin Inc. | Add +0.7% | 0.43% | −0.04 |
| ENGN Engene Holdings Inc. | Add +15.9% | 0.55% | −0.08 |
| SWTX Springworks Therapeutics Inc. | Add +3.9% | 3.93% | −0.23 |
| FDMT 4D Molecular Therapeutics Inc. | Add +0.9% | 1.41% | −1.13 |
Options Activity Q2 2024 → Q3 2024
| AXSM Axsome Therapeutics Inc. | call | New | 200,000 | $18.0M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 66 | $6.8B | GH, IMVT, GPCR, PCVX, ALNY |
| Q1 2026 | 62 | $4.8B | GH, IMVT, TARS, PCVX, GPCR |
| Q4 2025 | 53 | $4.4B | IMVT, GH, GPCR, TARS, DVAX |
| Q3 2025 | 56 | $3.6B | GH, IONS, CYTK, AKRO, APLS |
| Q2 2025 | 65 | $3.1B | GH, IONS, PTGX, DVAX, INSM |
| Q1 2025 | 69 | $3.1B | ITCI, GH, DVAX, IMVT, PTGX |
| Q4 2024 | 61 | $2.7B | DVAX, GH, ITCI, IMVT, APLS |
| Q3 2024 | 69 | $3.1B | ARGX, DVAX, GH, APLS, IMVT |
| Q2 2024 | 67 | $3.3B | AMGN, ARGX, AXSM, DYN, SWTX |
| Q1 2024 | 65 | $3.5B | SWTX, AMGN, APGE, INSM, DYN |